Molecular Partners Ag Stock Market Outlook
| MLLCF Stock | USD 2.25 0.00 0.00% |
Roughly 61% of Molecular Partners' investor base is looking to short. The analysis of overall sentiment of trading Molecular Partners AG pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Molecular Partners' historical and current headlines, can help investors time the market. In addition, many technical investors use Molecular Partners stock news signals to limit their universe of possible portfolio assets.
Comfort Level 39
Alarmed
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Molecular Partners' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Molecular Partners AG.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentWaiting |
Assuming the 90 days horizon and your typical level of risk aversion, our recommendation regarding Molecular Partners AG is 'Cautious Hold'. Macroaxis provides Molecular Partners buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding MLLCF positions.
Execute Molecular Partners Advice
The Molecular recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Molecular Partners AG. Macroaxis does not own or have any residual interests in Molecular Partners AG or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Molecular Partners' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Weakest | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
For the selected time horizon Molecular Partners AG has a Mean Deviation of 1.58, Standard Deviation of 4.82 and Variance of 23.21We provide investment recommendation to complement the last-minute expert consensus on Molecular Partners AG. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time. To make sure Molecular Partners is not overpriced, please verify all Molecular Partners AG fundamentals, including its price to earning, net income, book value per share, as well as the relationship between the revenue and total debt . Please also check out Molecular Partners shares owned by institutions to check your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.
Molecular Partners Trading Alerts and Improvement Suggestions
| Molecular Partners generated a negative expected return over the last 90 days | |
| Molecular Partners has high historical volatility and very poor performance | |
| The company reported the revenue of 9.33 M. Net Loss for the year was (63.78 M) with loss before overhead, payroll, taxes, and interest of (45.96 M). | |
| Molecular Partners AG has accumulated about 267.13 M in cash with (90.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 14.0% of the company outstanding shares are owned by corporate insiders |
Molecular Partners Returns Distribution Density
The distribution of Molecular Partners' historical returns is an attempt to chart the uncertainty of Molecular Partners' future price movements. The chart of the probability distribution of Molecular Partners daily returns describes the distribution of returns around its average expected value. We use Molecular Partners AG price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Molecular Partners returns is essential to provide solid investment analysis for Molecular Partners.
| Mean Return | -0.57 | Value At Risk | -3.61 | Potential Upside | 0.00 | Standard Deviation | 4.82 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Molecular Partners historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Molecular Partners Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Molecular Partners or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Molecular Partners' price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Molecular pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.61 | |
β | Beta against Dow Jones | 0.45 | |
σ | Overall volatility | 5.01 | |
Ir | Information ratio | -0.13 |
Molecular Partners Volatility Alert
Molecular Partners AG exhibits very low volatility with skewness of -4.53 and kurtosis of 33.77. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Molecular Partners' pink sheet risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Molecular Partners' pink sheet price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Molecular Partners Fundamentals Vs Peers
Comparing Molecular Partners' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Molecular Partners' direct or indirect competition across all of the common fundamentals between Molecular Partners and the related equities. This way, we can detect undervalued stocks with similar characteristics as Molecular Partners or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Molecular Partners' fundamental indicators could also be used in its relative valuation, which is a method of valuing Molecular Partners by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Molecular Partners to competition |
| Fundamentals | Molecular Partners | Peer Average |
| Return On Equity | 0.62 | -0.31 |
| Return On Asset | 0.32 | -0.14 |
| Profit Margin | 0.62 % | (1.27) % |
| Operating Margin | 0.61 % | (5.51) % |
| Current Valuation | (41.92 M) | 16.62 B |
| Shares Outstanding | 36.04 M | 571.82 M |
| Shares Owned By Insiders | 14.13 % | 10.09 % |
| Shares Owned By Institutions | 45.00 % | 39.21 % |
| Price To Earning | 1.74 X | 28.72 X |
| Price To Book | 0.91 X | 9.51 X |
| Price To Sales | 1.19 X | 11.42 X |
| Revenue | 9.33 M | 9.43 B |
| Gross Profit | (45.96 M) | 27.38 B |
| EBITDA | (60.67 M) | 3.9 B |
| Net Income | (63.78 M) | 570.98 M |
| Cash And Equivalents | 267.13 M | 2.7 B |
| Cash Per Share | 8.22 X | 5.01 X |
| Total Debt | 5.15 M | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 14.37 X | 2.16 X |
| Book Value Per Share | 7.73 X | 1.93 K |
| Cash Flow From Operations | (90.95 M) | 971.22 M |
| Earnings Per Share | 3.82 X | 3.12 X |
| Number Of Employees | 163 | 18.84 K |
| Beta | 0.62 | -0.15 |
| Market Capitalization | 237.9 M | 19.03 B |
| Total Asset | 172.67 M | 29.47 B |
| Z Score | 27.6 | 8.72 |
| Net Asset | 172.67 M |
Molecular Partners Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Molecular . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Molecular Partners Buy or Sell Advice
When is the right time to buy or sell Molecular Partners AG? Buying financial instruments such as Molecular Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Molecular Partners in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tips ETFs Thematic Idea Now
Tips ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Tips ETFs theme has 35 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tips ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Molecular Pink Sheet
When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:Check out Molecular Partners Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.